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Eukaryotic RNA polymerase II (RNAPII) not only synthesizes mRNA but also coordinates transcription-related processes via its
unique C-terminal repeat domain (CTD). The CTD is an RNAPII-speciﬁc protein segment consisting of repeating heptads with
the consensus sequence Y1S2P3T4S5P6S7 that has been shown to be extensively post-transcriptionally modiﬁed in a coordinated,
but complicated, manner. Recent discoveries of new modiﬁcations, kinases, and binding proteins have challenged previously
established paradigms. In this paper, we examine results and implications of recent studies related to modiﬁcations of the CTD
and the respective enzymes; we also survey characterizations of new CTD-binding proteins and their associated processes and
new information regarding known CTD-binding proteins. Finally, we bring into focus new results that identify two additional
CTD-associated processes: nucleocytoplasmic transport of mRNA and DNA damage and repair.
1.Introduction
Since its discovery by Fischer and Krebs in 1955 [1], the
reversible phosphorylation of proteins has been implicated
in the regulation of almost every aspect of cellular function,
including metabolism, cell division, diﬀerentiation, signal-
ing, and countless others. A particularly fascinating form of
this regulation is employed during the transcription of DNA
by RNA Polymerase II (RNAPII). Eukaryotic transcription
and the concomitant pre-mRNA processing require the
precise coordination between, and recruitment of, speciﬁc
setsoffactorsatspeciﬁcstagesofthetranscriptioncycle.This
coupling of transcription and associated processes has been
shown to be dependent on a particular feature of RNAPII,
the C-terminal repeat domain or CTD [2]. Distinguishing
RNAPII from its prokaryotic and eukaryotic (RNAPIII and
RNAPI) counterparts, the CTD is an extension of the
polymerase’s largest subunit, Rpb1, and is composed of a
tandem array of seven amino acid repeats with the consensus
sequence Y1S2P3T4S5P6S7. The number of these heptad
repeats varies from organism to organism and appears to
correlate with genomic complexity; there are 26 repeats in
yeast, 44 in Drosophila, and 52 in humans [3, 4]. Despite
being dispensable for the catalytic activity of RNAPII, the
CTD is conserved through evolution and is essential for
life; for example, removing two thirds of the CTD repeats
results in inviability [5, 6]. Although the function of the
CTD remained elusive for several years after its discovery,
research over the last three decades has conﬁrmed its role as
aselectiveandﬂexiblescaﬀoldfornumerousfactorsinvolved
in transcription (for reviews see [2, 7, 8]). The plastic
(both in terms of conformation and susceptibility to post-
translational modiﬁcation) and repetitive nature of the CTD
allows it to undergo a relatively well-characterized sequence
of phosphorylation and dephosphorylation events during
the transcription cycle (initiation, elongation, and termi-
nation), linking transcription with transcription-associated
processes in a temporal manner [2, 7, 9]. The CTD has
been shown to play a role in a wide variety of transcription-
associated functions, and its repertoire of binding partners,
modiﬁcations, and associated processes has grown rapidly
over the last few years.
The CTD’s unique structure, functional characteristics,
and fundamental role in transcription have generated a
substantial amount of interest and have made it the subject
of considerable study. This research has greatly expanded
our understanding of the CTD, its interacting factors, and
the process of transcription in general, but as demonstrated2 Genetics Research International
by recent discoveries of hitherto uncharacterized CTD
modiﬁcations, kinases, and binding factors/modes, there is
still much that remains to be learned. As the study of
gene expression and transcriptional control mechanisms
expands from preinitiation into elongation, a deeper and
more nuanced understanding of the CTD will likely become
essential in order to deconvolute the relationships between
various aspects of gene control. This is especially pertinent
in terms of understanding the crosstalk between transcrip-
tional elongation and co/post-transcriptional events, such
as splicing, export, and translation. In this review, we will
discuss recent developments and emerging paradigms in
the study of the CTD, its modiﬁcations, binding partners,
and associated processes. To further expand on an especially
relevant (in terms of transcriptional control) and newly
emerging CTD-associated process, we will also present an
in-depth discussion of the nuclear export of RNA, with a
particular focus on the interactions between the nuclear
export machinery, the CTD, and transcription.
2. Phosphorylation of the CTD of RNAPII and
theT ranscriptionC y cle:AGeneralM odeland
Its Limitations
ThebindingspeciﬁcityoftheCTD,andthereforetherecruit-
ment of particular factors, is determined by the CTD’s phos-
phorylation state, which undergoes a series of alterations
throughout the transcription cycle. Serine 2, serine 5, and
more recently serine 7 of the heptad repeat have been identi-
ﬁed as the primary targets for this transcriptionally regulated
phosphorylation. In the general model of the “phosphoCTD
cycle,” RNAPII is recruited for assembly at the promoter
with an unphosphorylated CTD; moreover, it appears that
CTD phosphorylation prior to preinitiation complex (PIC)
formation has an inhibitory eﬀect on transcription [10].
Upon PIC formation, the CTD is phosphorylated at the Ser5
and Ser7 positions; this is followed by an increase in Ser2
phosphorylation during elongation [11], yielding a CTD
that contains a mix of doubly (and when considering Ser7,
perhaps triply) phosphorylated repeats at Ser2 and Ser5 in
the center of the gene (reviewed in [2, 9]). As the polymerase
elongates towards the 3  end of the gene, Ser5-speciﬁc
phosphatases decrease the Ser5 phosphorylation levels (on
noncoding genes, Ser7P levels drop as well), leaving the
CTD phosphorylated at Ser2 to terminate transcription
(Figure 1(a)).However,theCTDofterminatingRNAPIImay
also be phosphorylated at Ser7 positions, as the Ser7 mark
has been reported to be present at high levels throughout the
entire transcription unit on many protein-coding genes [12].
Despite being highly intuitive, this gradient model of
the “phosphoCTD cycle” (i.e., high-to-low Ser5P levels and
low-to-high Ser2P levels as RNAPII moves across a gene,
with Ser7P throughout) is oversimpliﬁed for several reasons.
First, although the model accounts for variations in the
generalphosphorylationpatternoftheCTD(recognizingthe
presence of gene segments with high Ser5P, high Ser5/2P,
and high Ser2P levels), it fails to fully capture the highly
dynamic nature of the process. The phosphorylation state
of the CTD is likely to be in continuous ﬂux through-
out the entire transcription cycle, with multiple kinases
and phosphatases working together to maintain speciﬁc
phosphorylation patterns on particular subsets of heptads.
For example, it has been recently shown that the Ser7
phosphates at the 3  end of the gene are actually placed anew,
after being removed by an unidentiﬁed phosphatase [12]
(more on this below). Another complication is the existence
of speciﬁc patterns of phosphorylated repeats within the
CTD. Our understanding of this particular aspect of CTD
phosphorylation is entangled with some of the limitations
ofchromatinimmunoprecipitation(ChIP),themethodused
to characterize the phosphorylation state of the CTD at
diﬀerent positions within the transcription unit; thus it is
convenient to discuss both of these topics together. Although
ChIP can be used to measure the relative level of each phos-
phoCTD mark (Ser2P, Ser5P, or Ser7P) at a speciﬁc position
within a gene, the repetitive nature of the CTD makes it
impossible to determine exactly which of the 52 heptads (in
mammals) are phosphorylated. In addition, the particular
pattern of phosphorylated residues within each heptad and
within sequential heptad units is also unknown; therefore,
theSer2,5,and7phosphorylatedCTDofelongatingRNAPII
is likely to be composed of heptads phosphorylated at
one, both, all, and none of the relevant positions. Among
the many unanswered questions concerning the detailed
phosphorylation state of the CTD, an especially interesting
one concerns determinism: is the phosphorylation pattern
of a speciﬁc heptad at a particular position within a gene
exactly the same during each transcription cycle, or does
phosphorylation occur in a more stochastic manner? The
answer to these questions may lie within the processivity
of the CTD kinases, the extent to which they stimulate
each other’s activity, and the speciﬁcs of their antagonistic
relationship with the CTD phosphatases.
Discussion of CTD phosphorylation patterns also raises
an interesting point regarding the antibodies used to identify
the post-translationally modiﬁed heptads (both in ChIP
and Western blotting). It is worth reiterating that the
Ser5P to Ser2P gradient model presented above is almost
entirely based on the reactivity of these antibodies [13].
The most common phosphoCTD antibodies are the Ser2P-
speciﬁc H5 and the Ser5P-speciﬁc H14 [14]; however, there
are a multitude of other antibodies available against the
CTD, including the recent and well-characterized anti-
Ser2P 3E10 and anti-Ser5P 3E8 antibodies [15]. As might
be expected, the reactivity of these antibodies with their
speciﬁc phospho-epitopes is aﬀected by other modiﬁcations
within the heptad in question and the heptads around it.
For example, the Ser2P-speciﬁc H5 antibody binds to a
triheptad peptide phosphorylated on both Ser2 and Ser5
with greater aﬃnity than to a triheptad containing only
Ser2P [16]. More impressive examples are the complete lack
of H14 reactivity to a single S5P in the ﬁrst repeat of a
diheptad peptide and the inability of 3E10 to detect an
S2P followed by an S5P in the next heptad [15]. Thus, the
phosphoCTD antibodies are multiheptad pattern speciﬁc,
and it appears that many CTD-binding proteins are asGenetics Research International 3
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Figure 1: Revised “phospho-CTD cycle.” (a) (I) For protein-coding genes, RNAPII is recruited to the promoter with an unphosphorylated
CTD (IIA form); moreover, it appears that CTD phosphorylation prior to preinitiation complex (PIC) formation has an inhibitory eﬀect
on transcription. (II) Upon preinitiation complex formation, the CTD is phosphorylated at the Ser5 (black) and Ser7 (red) positions. (III)
During elongation, an increase in Ser2 phosphorylation (green) produces the hyperphosphorylated form of the CTD, which is probably
an ensemble of singly, doubly, and triply phosphorylated heptads. (IV) As the polymerase elongates towards the 3  end of the gene, the
activity of Ser5-speciﬁc phosphatases decreases the Ser5 phosphorylation levels, while the Ser2 and Ser7 phosphate levels remain largely
unchanged. (b) (I) For noncoding genes, RNAPII is also recruited to the promoter with an unphosphorylated CTD (IIA form), and CTD
phosphorylation prior to preinitiation complex (PIC) formation seems to inhibit transcription. (II) Upon preinitiation complex formation,
the CTD phosphorylation of Ser5 (black) and Ser7 (red) increases. (III) During elongation, Ser2 phosphorylation (green) increases, while
Ser7 phosphorylation begins to decline, presumably due to the activity of a yet unidentiﬁed Ser7 phosphatase. (IV) At the 3  end of the gene,
the activity of Ser5-speciﬁc phosphatases decreases the Ser5 phosphorylation levels, Ser7 phosphorylation levels continue to decrease, and
Ser2 phosphate levels remain largely unchanged.
well (see below); this correlates nicely with evolutionary
studies that implicate heptad pairs as the functional unit of
the CTD [17, 18]. These observations suggest that the in-
depth characterization of CTD modiﬁcation patterns will
be important for a comprehensive understanding of factor
recruitment/binding and is not a purely academic exercise.
Although the ramiﬁcations discussed above (along with a
few others, such as epitope masking (for a more detailed
discussion see [2])) do not in any way invalidate phospho-
CTD ChIP, they should be kept in mind when interpreting
such data.
The general model of the phospho-CTD cycle also fails
to account for exceptions to the canonical patterns of
phosphorylation. The recent publication of three genome-
wide studies of phosphoCTD RNAPII occupancies in yeast
[12, 19, 20] has allowed for the veriﬁcation of the S5P
to S2P gradient model at high resolution across the entire
genome. Overall, the general model appears to hold for the
majority of genes [19, 20]; however, there seem to be a
number of exceptions to the deﬁned norm. The extent of
these exceptions has led the authors of one of the studies
to call for a reanalysis of the accepted paradigm [12], while
the other two groups ﬁnd that the general pattern occurs
globally [20] or near globally with some stipulations [19]. It
should be noted that the discrepancies between these studies
might be due to the diﬀerent methods used to bin/cluster
genes into “average transcription units” for analysis. This
binning,whichisoftenlimitedbypolymeraseoccupancyand
complicated by gene length and the presence of neighboring
transcription units, is especially challenging due to the
compact nature of the yeast genome. One consensus that
appears to emerge from the genome-wide studies is that
diﬀerent classes of RNAPII-transcribed genes have diﬀerent
CTD phosphorylation proﬁles. Examples include the high
levels of Ser7P throughout the length of protein-coding
genes (as compared to its decrease 5  to 3  on noncoding
genes), markedly lower levels of Ser2P on noncoding genes,
and enrichment/preference for speciﬁc modiﬁcations on
genes for snRNAs, cryptic unstable transcripts (CUTs),
stable untranslated transcripts (SUTs), genes of diﬀerent
lengths, and genes with diﬀerent promoter classes [19, 20].
These phosphoCTD variations correlate with the diﬀerent
requirements for the termination and processing of distinct
transcript types and make intuitive sense in the light of the4 Genetics Research International
CTD’s role during transcription. Therefore, future versions
of the “phosphoCTD cycle” will need to take such class-
speciﬁc diﬀerences into account. In our revised model, we
chose to separate the general cycle into two broad, but
distinct gene classes: protein-coding and noncoding genes
(Figures 1(a) and 1(b)) .H o w e v e r ,t h i sr e v i s e dm o d e li ss t i l l
an oversimpliﬁed representation of a complex process and
should be viewed as such.
3. Other Post-TranslationalModiﬁcations of
the CTD
Lastly (in terms of complications), it has not escaped notice
that modiﬁcation of the CTD is not theoretically limited
to the phosphorylation of Ser2, Ser5, and Ser7. Many
other post-translational modiﬁcations have been observed,
including phosphorylation of Tyr1 [21]a n dT h r 4[ 22]a n d
glycosylation [23]; however, the extent and transcriptional
functions of these modiﬁcations are currently unknown (for
more discussion, see [8]). These “noncanonical” modiﬁca-
tions, once fully characterized as functionally signiﬁcant,
have the potential to expand the CTD code further and
redeﬁne aspects of the general model; Ser7, a relative
newcomertothegeneralparadigm,isagoodexampleofhow
this can occur.
Yet another important CTD modiﬁcation, which until
recentlyhadnotbeendirectlyobservedtoplayadirectrolein
factor binding, is the enzymatic isomerization of the heptad
repeat’s peptidyl-proline bonds. Although multiple studies
havesuggestedarolefortheCTD-interactingpeptidyl-prolyl
cis/trans isomerases (Ess1 in yeast and Pin1 in humans)
in transcription and CTD phosphorylation [24–26], all of
thestructuresofCTD-substrates/CTD-bindingproteincom-
plexes revealed the CTD proline residues to be exclusively
in the more energetically stable, and therefore predominant,
transstate.Thischangedlastyearwhentwostructuralstudies
found that the Ser5-speciﬁc CTD phosphatase Ssu72 bound
to the cis conformation of an Ser5-Pro6 motif within the
heptad repeat [27, 28]. Concordantly, the activity of the
proline isomerase Ess1 was found to facilitate the rapid
dephosphorylation of the CTD by Ssu72 in vitro, suggesting
that this cis/trans interconversion plays a role in the ﬁne-
tuning of the phosphorylation state of the CTD [27]. These
ﬁndings have broad implications for CTD biology, both by
increasing the number of distinct CTD states and serving as
aregulatorymechanismforCTDphosphorylation.However,
it still remains to be determined whether proline isomeriza-
tion is a general property of RNAPII transcription or if it is
gene speciﬁc [27], a distinction that may apply to other types
of modiﬁcations as well.
A good example of a transcript class-speciﬁc CTD
modiﬁcation is the newly discovered methylation of an
arginine (R1810) in heptad 31 of the human CTD [29].
As an apology for the arginine (one of two in the human
CTD), it should be noted that while the ﬁrst 26 repeats
of the human CTD conform strongly to the consensus
sequence (YSPTSPS), there is signiﬁcant divergence from the
consensus in the C-terminal half of the CTD [30]. It has
been previously postulated that the various noncanonical
heptads (and even particular segments of the CTD; such
as the N- and C-termini [31]) may have speciﬁc functions,
and this arginine methylation seems to be a case in point
(for further discussion, please see [30]). Mediated by the
methyltransferase CARM1 and inhibited by Ser5 and Ser2
phosphorylation, the methylation appears to repress the
expression of snRNAs and snoRNAs in a general manner
[29]. This and other modiﬁcations of the noncanonical
heptads may serve as a discriminatory mark for RNAPII
recruited to particular genes or transcript classes. It should
also be noted that Ser7P is currently thought to be transcript
class-speciﬁc CTD modiﬁcation, as Ser7 to alanine muta-
tionsintheCTDcauseadefectinsnRNAtranscriptionwhile
having little eﬀect on protein-coding genes [32]. However,
the ubiquitous nature of Ser7P on protein-coding genes,
along with the ﬁnding that Ser7 is enriched on RNAPII
within introns [19], argues for some (perhaps more subtle)
functional role for Ser7P on most transcription units.
Thus, the general “phosphoCTD cycle” has given way
to a “CTD code” of staggering complexity, one that we
are just beginning to explore in detail. This complexity
reﬂects the vast number of diﬀerent genes, processing events,
and transcriptional programs that RNAPII must coordinate.
Although the segmented gradient model has proven to
be very useful for conveying the CTD’s principal function
during RNAPII transcription, as our understanding of the
CTD and associated processes improves, it is likely to
undergo drastic changes in the near future. Understand-
ing the nuances of this CTD code will be imperative to
understanding the link between transcription and cotran-
scriptional events and to perhaps eventually unlock the
therapeutic potential of the CTD.
4. The CTDKinases
The speciﬁc phosphorylation events within the heptad
repeat are mediated through the activity of a transcription-
associatedsubsetofcyclin-dependentkinases(CDKs)known
as the CTD kinases. Unlike their cell cycle counterparts,
the CTD kinases form complexes with members of the
noncycling “transcription cyclin” family and are active
throughout the cell cycle. Nevertheless, CTD kinase activ-
ity is tightly regulated through a variety of mechanisms,
including selectiverecruitment,binding bykinase-associated
factors, and sequestration by inhibitory factors. Although
somewhat promiscuous in vitro (for example, the Ser2-
speciﬁc CTD kinase Ctk1 can phosphorylate both Ser2
and Ser5 in vitro [16]), in vivo the CTD kinases are
selective for particular heptad residues (Ser2, 5, and 7) and
stages of transcription. Thus, the various CTD kinases are
most conveniently presented in the context of a segmented
transcription cycle; however, it should be made clear that in
reality the various kinase activities lack the clearly delineated
boundaries that such a presentation suggests.
Although we will not be discussing them in detail, it
should be kept in mind that the CTD kinases function in
conjunction with the more enigmatic CTD phosphatasesGenetics Research International 5
(several of which have been characterized in yeast, including
Fcp1 [33], Ssu72 [34, 35], and Rtr1 [36]; see [7]f o rar e v i e w
and [9] for further discussion).
4.1.InitiationandthePromoter:CDK7andCDK8. Thephos-
phorylation of CTD Ser5 and Ser7 residues during the for-
mation of the preinitiation complex is mediated by the CTD
kinase subunit of the general transcription factor TFIIH:
Kin28/Ccl1 in yeast and CDK7/CyclinH in metazoa [11, 13,
37–39]. In an elegant interplay, the kinase activity of Kin28
is stimulated by the mediator coactivator complex, which
binds to, and delivers, unphosphorylated RNAPII to the
promoter [40]. The resulting phosphorylation of the CTD
leads to the dissociation of mediator [41]; thus after fulﬁlling
its function, mediator is able to use the CTD and Kin28 to
induce its own release from transcriptionally active RNAPII.
Intriguingly, a subpopulation of the mediator complex has
been found to include an extra module that contains the
CDK8/CyclinC (Srb10/Srb11 in yeast) kinase/cyclin pair.
Initially discovered as a suppressor of a CTD truncation [42],
CDK8 has emerged as the only CTD kinase to be implicated
in the repression of transcription. Concordant with the
process of mediator release, one of the mechanisms by which
CDK8 has been proposed to execute its inhibitory activity is
through the premature phosphorylation of the CTD (prior
to PIC formation) and inactivation of the CDK7/CyclinH
complex[10,43].Althoughhistoricallythefocushasbeenon
CDK8’s role asnegative regulatorof transcription, increasing
numbers of studies are ﬁnding that CDK8 can also play
a positive role in transcriptional activation. Therefore, a
complete understanding of the function of CDK8 in CTD
phosphorylation and transcription remains elusive and is
likely to be a topic of much research in the near future (for
more details and a comprehensive review, see [7, 44]).
Once thought to be essential for promoter clearance,
the activity of Kin28 has been shown to be dispensable for
global gene transcription [45, 46]. Despite this, Kin28 has
beenfoundtoenhancepolymeraseprogressionthroughlong
genes in yeast (over 2 kb), suggesting that it plays a role in
transcriptional elongation or in the inhibition of premature
termination [19]. CDK7 also takes part in the phosphory-
lation and activation of other CDKs (see [47] for a review);
however,its(andSer5Ps)mostclearlydeﬁnedtranscriptional
role is the recruitment of the 5  end capping machinery. Not
only does this ensure the proper processing of the nascent
mRNA, it has also been shown to mediate the recruitment
of the Ser2 CTD kinases in some organisms (either directly
or through recruitment of the capping machinery) [48–50];
this suggests that phosphorylation of Ser5 plays a role in
triggering the onset of Ser2 phosphorylation.
4.2. The Elongation Phase: Ctk1, Bur1, and Their Metazoan
Counterparts. Subsequent to Kin28 activity at the promoter,
phosphorylation of Ser2 of the CTD heptad occurs down-
streamofthetranscriptionstartsite(TSS)andcoincideswith
RNAPII entry into productive elongation. Coupled with the
activity of Ser5P-speciﬁc phosphatases (Rtr1 in yeast [36]),
this leads to a transition from high Ser5P to high Ser2P (as
characterized by ChIP). The Ser5P to Ser2P crossover point,
deﬁned as the point at which the ChIP signals for the two
CTD marks cross, is on average ∼450 bp downstream of
the TSS and appears to be independent of the overall gene
length [19]. This implies that the dynamics of Ser2 and Ser5
phosphorylation are not scaled to gene length; however, the
signiﬁcance of the crossover point in terms of the actual
phosphorylation state of the CTD is obscure.
In Saccharomyces cerevisiae (Sc), the phosphorylation
of Ser2 is primarily mediated by CTDK-I, a three subunit
enzyme (consisting of Ctk1, a CDK homologue; Ctk2, a
cyclin homologue; and Ctk3, whose function is unknown)
[51, 52]. Although it is responsible for the bulk of Ser2
phosphorylation in vivo, Ctk1 is not essential for viability
or for transcriptional elongation. The CTD kinase activity
of Ctk1 has been linked to several transcription-associated
processes, including the recruitment of the Set2 histone
methyltransferase [53, 54], 3  end processing [19, 55, 56],
and termination (reviewed in [9]). In addition to its role
as a CTD kinase, Ctk1 (independent of its kinase activity)
has also been shown to be involved in the dissociation of
basaltranscriptionfactorsfromRNAPII[57].Despitehaving
a principal role in CTD Ser2 phosphorylation, Ctk1 is not
the only Ser2 kinase in yeast; it coexists with the essential
Bur1 kinase (which consists of the CDK homologue Bur1
and the cyclin Bur2) [58]. While it has been proposed
that Bur1’s primary transcription-related substrate is the
elongationfactorSpt4/5[59,60],ratherthantheCTD,recent
evidence indicates that Bur1 binds to the Ser5P CTD and
contributestoSer2phosphorylation duringearlyelongation,
possibly stimulating subsequent Ctk1 activity [49, 61]. As
mentioned previously, Bur1 has also been found to exhibit
an elongation phase Ser7 kinase activity, which appears to
counteract the activity of a yet unidentiﬁed Ser7 phosphatase
[12]. Another pair of Ser2 elongation kinases is also present
in the ﬁssion yeast Saccharomyces pombe (Sp), where Lsk1,
the Sp orthologue of Ctk1, has been shown to be responsible
for the bulk of Ser2 phosphorylation, while Sp CDK9, the Sp
orthologue of Bur1, is able to phosphorylate both the CTD
and Spt5 [50, 62].
Until recently, higher eukaryotes appeared to have only
one Ser2 CTD kinase: P-TEFb (which is composed of CDK9
and cyclinT). P-TEFb is able to phosphorylate both the
Ser2 position of the CTD and the elongation factor Spt5
and is essential for transcriptional elongation [63–65]( f o r
detailed discussions, see [66–68]). The substrate speciﬁcity
of P-TEFb, coupled with its equal sequence similarity to
both Bur1 and Ctk1, has led to the proposal that P-
TEFb reconstitutes the activities of both yeast kinases in
higher eukaryotes [69]. However, there was some evidence
that this may not be the case; two evolutionary studies
concluded that while Sc Bur1 is the closest Sc relative of
metazoan CDK9 proteins, Sc Ctk1 is actually more closely
related to another set of relatively little-studied metazoan
CDK proteins [70, 71]. Based on these evolutionary studies,
work in our lab has characterized the previously unstudied
Drosophila CDK12 (dCDK12) and little-studied human
CDK12 (hCDK12) as elongation phase CTD kinases and
the metazoan orthologues of yeast Ctk1 [72]. Unlike most6 Genetics Research International
other cell cycle and transcriptional CDKs, CDK12 (and
CDK13, a highly related paralogue absent in Drosophila
but present in many “higher” organisms) contains splicing
factor-related structural features (RS domains) and has
been previously implicated in the regulation of alternative
pre-mRNA splicing [73–77]. Although both CDK12 and
CDK13 manifest CTD kinase activity in in vitro kinase
assays, only CDK12 seems to have an eﬀect on global CTD
phosphorylation in vivo; thus CDK13’s role in transcription
(assuming one exists) remains elusive [72]. In terms of the
cyclin partner of CDK12, our lab found that endogenous
dCDK12 associates with cyclinK, a Ctk2-like cyclin that has
been previously characterized as an alternative partner for
CDK9 [78]. These ﬁndings are inconsistent with previous
reports that CDK12 and CDK13 interact with the L class
cyclins [74, 75]; thus, whether cyclinK is the cyclin partner
of human CDK12 and CDK13 remains to be determined. As
of this paper, other than our initial characterization, there
have been no published studies of CDK12 and CDK13 in the
context of transcription and transcriptional elongation, thus
muchremainstobelearnedaboutthesekinases.Intriguingly,
the depletion of dCDK12 aﬀects the phosphorylation state of
the CTD without aﬀecting RNAPII occupancy (BB and ALG,
unpublished); therefore, CDK12 might prove to be a useful
tool for studying the links between CTD phosphorylation
patternsandtranscriptionelongation-associatedprocessesin
higher eukaryotes.
A ﬁnal point regarding the CTD kinases relates to their
therapeutic potential. As the CTD kinases are involved in
the coupling of various signaling pathways to transcription
and RNA processing events, they play important roles in the
regulation of cell growth, proliferation, and survival. Thus,
targeting these kinase activities may be potentially useful for
the treatment of human diseases and cancer [79]. In fact, the
CDK inhibitor ﬂavopiridol, which targets P-TEFb, is used for
the treatment of some forms of leukemia, and P-TEFb has
been implicated in HIV replication [80, 81]. The emerging
links between the CTD and DNA repair/genomic stability
(see below), combined with the fact that ∼15% of disease-
causing mutations are a consequence of the misregulation
of alternative splicing [82] (a function associated with both
the CTD and CDK12/13, see below), suggest that a more
comprehensive understanding of the CTD and its kinases
could have broad medical implications in the future.
5. CTD Functions
T h eC T Dh a sb e e ni m p l i c a t e di nab r o a ds p e c t r u mo ft r a n -
scription-associated functions, and its collection of binding
partners has continued to expand over the last few years.
Important target processes include mRNA (and snRNA)
capping, splicing, 3  end processing, termination, and more
recently nuclear export (discussed below). In terms of
non-RNA processing-associated events, the CTD has been
showntoplayrolesintranscriptionalactivation,cotranscrip-
tional chromatin modiﬁcation, chromatin remodeling, and
genome stability. Of course, the analysis of the CTD’s role
in each speciﬁc function is very challenging, as many of the
CTD-mediated transcriptional processes are interlinked. For
example,cappinghasbeenshowntoinﬂuenceboththesplic-
ing of the ﬁrst intron and 3  end processing [83–87]; splicing
of the last intron aﬀects 3  end processing and vice versa
[88–90]; and alternative splice site choices are aﬀected by the
cotranscriptional histone modiﬁcations at splice site junc-
tions [91–93]. While these interactions demonstrate the high
degree of coordination involved in mRNA synthesis, they
unfortunately complicate the interpretation of functional
studies. In a broad sense, it is fair to state that exactly how S2,
S5, and S7 phosphorylation aﬀect initiation, elongation, and
terminationremainspoorlyunderstood.Despitethelackofa
universal understanding, particular aspects of CTD function
have been characterized to an impressive level of detail, and
many of the more enigmatic functions are becoming better
understood through continued investigation. In the next
few sections, we present a rather cursory overview of the
functions of the CTD (for other reviews, see [2, 7, 8]) before
moving on to a discussion of two newly emergent CTD-
related functions: mRNA export and DNA repair/genomic
stability.
5.1. 5  Capping. As mentioned previously, one of the most
clearly recognized functions of the CTD is its involvement
in the 5  end capping of mRNA through the recruitment of
the capping machinery. The modiﬁcation of the 5  end of
the RNA with the 5  7-methyl guanosine cap is unique to
RNAPII transcripts and occurs just after the transcript clears
the polymerases exit channel [94, 95]. Transcripts made by
a CTD-less RNAPII were found to be ineﬃciently capped,
leading to the characterization of the physical interaction
between the capping enzymes and the phospho-CTD [96–
98]. Subsequent studies showed that the capping enzyme
associates with the 5  end of genes in vivo,w h i c hc o r r e l a t e s
with the enzyme’s function, and that this association is
dependent on phosphorylation of Ser5 of the CTD [11, 37,
46]. In addition to raising the local concentration of the
cappingenzymeneartheexitchannel,theCTDhasalsobeen
showntostimulateitsactivity.Anexampleofaphosphoryla-
tion state-speciﬁc function, mammalian guanylyltransferase
was found to bind to both Ser2P and Ser5P synthetic heptad
repeats but was allosterically activated only by Ser5P [99].
The interaction between the 5  capping machinery and
the CTD has also been investigated structurally, resulting
in some interesting insights. The crystal structure of the
Candida albicans guanylyltransferase Cgt1 complexed with a
synthetic Ser5P four heptad repeat peptide revealed that the
CTD binds within an extended docking site on the enzymes
surface using two nonadjacent heptads, and a full-heptad
repeat was looped out away from the interaction site [100].
This looping not only demonstrates the inherent ﬂexibility
of the CTD but also suggests that by binding two remote
heptads, CTD binding factors may be able to loop out large
portions of the CTD. This looping could potentially result
in the formation of novel structural motifs, which could in
turn serve as binding sites for other CTD binding factors,
leading to organized, sequential binding [7]. Whether this
actually occurs is still an open question; however, recentGenetics Research International 7
studies have shown that the binding of some well-known 3 
end processing factors to the CTD appears to be cooperative
in nature [101].
5.2. 3  End Processing. Another well-recognized function of
the CTD is its role in 3  end processing and termination (for
reviews, see [102, 103]). Analogous to capping, transcription
by a CTD-less RNAPII was shown to aﬀect both processes,
and cleavage and polyadenylation factors were found to bind
to the phospho-CTD [104–110]. Accordingly, inhibition of
Ctk1 in yeast has been shown to decrease the eﬃciency of
cleavage at poly(A) sites [56] and result in the disruption
of polyadenylation factor recruitment to the 3  end of the
gene [55]. A genome-wide analysis has also shown that
depletion of Ctk1 using a tetracycline-repressible degron
mutant causes a “pileup” of polymerases at the poly(A)
site in a subset of genes with good consensus poly(A)
sequences [19]. This increase in RNAPII occupancy suggests
that improper CTD phosphorylation at these sites can result
in a strong transcriptional pause that is perhaps due to the
rate-limiting recruitment of a speciﬁc factor. Strongly linked
to polyadenylation, termination has also been reported to be
aﬀected by the CTD [108]; in addition, Rtt103, a component
of the termination complex, has been shown to bind Ser2P
CTD [111]. However, the role of CTD modiﬁcation in
termination is not yet well understood (see [9, 103, 112]f o r
further discussion). Intriguingly, it has been observed that
the recruitment of one well-recognized CTD binding 3  end
processing factor, Pcf11 (which preferentially binds to Ser2
phosphorylated CTD), does not directly correlate with the
level of Ser2 CTD phosphorylation [20, 55, 106]; analysis by
ChIP indicates that Pcf11 is recruited mainly at the poly(A)
site, while Ser2P levels rise throughout the coding region.
Potential explanations for this phenomenon highlight some
of the interesting complications surrounding phospho-
CTD factor recruitment. Perhaps Pcf11 requires a certain
threshold of Ser2P or both Ser2P and an external signal, such
as the presence of the newly synthesized polyadenylation site,
the unmasking of particular CTD epitopes, or the presence
additional factors (Pcf11 CTD binding was recently shown
to be cooperative [101]). Other considerations include the
remodeling of the CTD via a pattern-speciﬁc change (such
as the formation of Ser2P only heptads) or modiﬁcations
that are undetectable by ChIP. With regards to the latter
and the previous discussion on proline isomerization, Pcf11
wasreportedtospeciﬁcallyrecognizethreeneighboringtrans
prolines within a mixed population of cis-trans isomers
[113]. It is likely that the recruitment of many other
CTD-binding factors is also mediated through multiple
mechanisms and dependent on the satisfaction of particular
sets of conditions.
5.3. snRNA Processing. One of the relatively more recently
discovered functions of the CTD is its role in the tran-
scription and 3  end processing of snRNAs [114, 115]. Even
though they are transcribed by RNAPII, snRNAs are unlike
most coding transcripts; they do not undergo splicing or
polyadenylation and instead rely on a conserved 3  box RNA
processing element downstream of the coding region for
proper 3  end processing and termination [116]. The 3  end
processing of snRNAs has received a lot of recent attention,
as it is currently the only speciﬁc function attributed to the
phosphorylationofSer7oftheheptadrepeat[32].Seemingly
dispensable for viability and expression of protein-coding
genes, Ser7 has been found to be essential for endogenous
snRNA gene expression. This requirement for Ser7 phospho-
rylation was subsequently linked to the integrator complex
[32], a large CTD-associated multiprotein complex involved
in snRNA 3  end processing [117]. Further characterization
of the CTD-integrator interaction not only revealed that
both Ser2P and Ser7P were required but also that eﬃcient
binding required a speciﬁc arrangement of the modiﬁcations
[118]. Screening of synthetic diheptad repeats revealed that
although maximal binding was achieved with both Ser2
and Ser7 phosphorylated repeats, the minimal interaction
domain consisted of a Ser7P on the ﬁrst heptad followed
by a Ser2P on the second heptad; any other combination of
two phosphates was insuﬃcient for integrator binding [118].
These ﬁndings lend further support for the pattern-speciﬁc
binding of CTD-associated factors and, coupled with the fact
that integrator is speciﬁc to snRNA genes, also suggest that
the appropriate Ser2P/Ser7P patterns may be snRNA gene
speciﬁc (although many other discriminatory mechanisms
couldbeatplay,suchasthepreviouslydiscussedmethylation
of R1810).
5.4. Histone Modiﬁcations. Tying together two important
aspects of gene expression and transcriptional coordination,
the CTD has also been shown to be involved in the co-
transcriptional modiﬁcation of histones and remodeling of
chromatin structure. Although a full discussion of histone
modiﬁcations and the histone code hypothesis is beyond the
scope of this paper, the signiﬁcance of these processes cannot
be understated: they play integral functions in almost every
aspect of gene expression and regulation (for a review, see
[119]). Here, we will only give a very brief overview of some
CTD-related functions and a short list of new developments.
Providing the ﬁrst clear link between the CTD and his-
tonemodiﬁcation,theyeastSet1andSet2methyltransferases
were found to be recruited to actively transcribed genes
at speciﬁc stages of the transcription cycle (5  end versus
interior of the gene, resp.) through interactions with the
Ser5P (via the PAF complex for Set1) and Ser2/5P CTD
[120–123]( s e e[ 124] for a review). Thus, Set1’s activity, the
methylation of histone H3 at the K4 position, peaks near
the promoter, while Set2’s methylation of H3 at K36 occurs
downstreaminthecodingregion.TheH3K36trimethylation
mark can be used to identify transcriptionally active genes
and has been shown to suppress inappropriate transcription
from cryptic promoters, which was initially thought to occur
through the recruitment of the histone deacetylase Rpd3S
[125, 126]. Surprisingly, recent studies have found that
Rpd3Sisactuallyrecruitedviadirectbindingtothephospho-
CTD; although H3K36 trimethylation is dispensable for
Rpd3S recruitment, it appears to be required for activation8 Genetics Research International
of its deacetylation activity [127, 128]. Intriguingly, Set2 is
capable of H3K36 dimethylation independent of its CTD-
interacting SRI domain or Ctk1 [54], implying that only one
speciﬁc aspect (H3K36 trimethylation) of Set2’s activity is
regulated by interaction with the phospho-CTD. Another
interesting chromatin-related CTD binding factor is the
histone H3 chaperone and transcription elongation factor
Spt6 [129]. Spt6 has been shown to bind the Ser2P CTD
through a tandem SH2 domain [130] and interact with
the multifunctional elongation factor IWS1/Spn1, an Spt6-
interacting factor that associates with the nuclear RNA
export factor REF1/Aly (and Yra1 in yeast (ALM and ALG,
unpublished)) and possibly facilitates nuclear export [129].
In addition to its association with REF1/Aly, IWS1/Spn1 has
been recently found to be required for the optimal loading
of the mammalian Set2 (HYPB/Setd2) in the coding regions
of several genes [131], linking nucleosome reassembly with
elongation-coupled H3K36 trimethylation in vivo.S e v e r a l
other recently characterized chromatin-related CTD interac-
tions include the recruitment of the chromatin-remodeling
factorCHD8[132]andtheFACThistonechaperoneviaHP1
[133].Thenumberofrecognizedchromatin-associatedCTD
interacting factors is likely to grow rapidly over the next few
years as our understanding of both the processes of, and
the relationship between, CTD phosphorylation and histone
modiﬁcation improves.
5.5. Splicing. One of the more intriguing but relatively
poorly characterized functions of the CTD is its involvement
in cotranscriptional splicing (for reviews, see [134, 135]).
Although neither active transcription nor the CTD is
absolutely required for splicing (presynthesized mRNAs can
be spliced by injection into Xenopus oocytes or by incu-
bation with nuclear extracts [136]), experimental evidence
accumulated over the last three decades implicates the CTD
as a key player in the coupling between the two processes.
The link between the CTD and splicing was ﬁrst proposed
in the early 90s [137], and in the mid-to-late 90s, the
hyperphosphorylated RNAPII was shown to associate with
the SR (Serine/Arginine rich) family of splicing factors and
with components of the splicing machinery [138–140]. Con-
cordantly transcription by a CTD-less RNAPII was shown
to result in low splicing eﬃciency in vivo [108], and the
addition of an anti-CTD antibody or exogenous expression
of CTD peptides resulted in the accumulation of unspliced
transcripts [140] and the nuclear reorganization of splicing
factors [141]. In what could be considered the reciprocal
experiment, it was also shown that isolated CTD fragments
and puriﬁed phosphorylated RNAPII were able to activate
splicing reactions in vitro [142, 143]. In addition to the SR-
likeCTD-associatedfactors(SCAFs)[140,144],severalother
CTD-binding splicing factors have been identiﬁed, including
the yeast U1 snRNP component Prp40 [145] and the
mammalian splicing factors CA150 (TCERG1) [146], PSF,
and p54/NRB [147]. A recent addition has been the splicing
factor U2AF, which in an in vitro complementation assay was
shown to be recruited to the CTD in complex with another
splicesome component, Prp19, in order to overcome a weak
polypyrimidine-binding tract in an IgMA3 substrate [148].
Although alternative splicing has been directly demonstrated
to be aﬀected by the presence of the CTD [149], the fact
that RNAPII elongation rate has also been implicated in
splicesitechoice[150,151]hasmadeitdiﬃculttodetermine
how much of the eﬀect is due to the speciﬁc recruitment
of splicing factors to the CTD and how much is due to
changes in the elongation rate (kinetic coupling) or other
processes. One study that merits speciﬁc mention is that
of Batsche et al., who reported that the inclusion of a
set of alternative exons in the middle of the CD44 gene
was dependent on the site-speciﬁc accumulation of RNAPII
eoccupancy induced by the catalytic subunit of the SWI/SNF
chromatin-remodeling complex [152]. Surprisingly, this
“stalled” RNAPII exhibited a SWI/SNF-dependent switch
of the RNAPII phosphorylation status from the elongation
characteristic Ser2P to the more promoter characteristic
Ser5P, which perhaps creates a barrier to further elongation
(for a detailed discussion regarding kinetic coupling please,
see[134]).Inadditiontoitsgeneralroleintherecruitmentof
splicing factors, it has also been suggested that the CTD may
function as a molecular tether for distant splice sites within
themRNA.Thiswouldbeaccomplishedthroughthebinding
of the nascent 3  splice site to a CTD-associated splicing
factor, thus eﬀectively immobilizing it near the polymerase
mRNA exit channel in anticipation of the cognate 5 
splice site. Enhancement of the local concentration of the
splice sites would then dramatically increase the eﬃcacy
of the splicing reaction (see [135]). This tethering model
is especially attractive in higher eukaryotes in which the
intron lengths of many genes exceed thousands of base pairs.
Although studies have demonstrated that mRNA tethering is
likely [153], it has yet to be directly linked to the CTD and its
phosphorylation.
Although it is not the only CDK kinase to have been
implicated in the regulation of both transcription and
alternative splicing (CDK11/cyclinL has been shown to aﬀect
both processes but lacks a reported CTD kinase activity [154,
155]), CDK12’s CTD kinase activity coupled with its struc-
tural and functional characteristics places it directly at the
juncture between transcription, the CTD, and splicing. The
N-terminal domains of both CDK12 and its more enigmatic
paralogue CDK13 contain arginine/serine (RS) dipeptide-
richsegments,whicharecharacteristicofsplicingfactorsand
splicing factor regulators and are believed to be important
for protein-protein interactions [156, 157]. Much like other
RS domain-containing proteins and most factors involved
in pre-mRNA splicing, CDK12 and CDK13 were found to
exhibit a punctate pattern of localization in the nucleus,
superimposed on a more even distribution throughout the
nucleoplasm. The punctate localization points appear to
represent “nuclear speckles” [76, 77], commonly thought to
be sites of splicing factor storage [158]. In accordance with
these structural features and localization, in vivo splicing
assays using reporter genes have demonstrated that the
ectopic overexpression or depletion of CDK12 and CDK13
modulates alternative splice site selection [74, 75, 77].
In addition, CDK13 was observed to aﬀect HIV splicing
in a Tat-dependent manner [73]. These splicing eﬀectsGenetics Research International 9
were postulated to be a consequence of CDK13-mediated
phosphorylation of the canonical SR splicing factor ASF/SF2
[76], but all of the extant studies utilized ectopic overexpres-
sion of CDK12 and CDK13, usually without their potential
cyclin partners, in assay systems that can detect splice site
changes but are unable to provide mechanistic insights.
Moreover, many of the results appear to argue against the
direct phosphorylation of speciﬁc splicing factors by CDK12
and13;forexample,theN-terminiofCDK12and13areable
to aﬀect splicing independently of the kinase domains; and
one study has reported that the phosphorylation of ASF/SF2
byCDK13appearstobeindirect[74].Complicatinganalyses
of this type is the fact that the overexpression of virtually
any SR protein will have eﬀects on splicing via sequestration
of other SR proteins (and SR protein-binding partners),
competition for SR phosphorylating and dephosphorylating
factors, and the occurrence of other nonspeciﬁc and unfore-
seen events; thus, it is diﬃcult to amalgamate the current
data into an overall consensus. Despite these caveats, the
unusualstructuresofCDK12andCDK13,coupledwiththeir
ability to modulate splice site choices in in vitro assays, make
it tempting to speculate that the two kinases may serve as
a central link between the processes of transcription, CTD
phosphorylation, and splicing; however, whether such a link
exists is still undetermined.
5.6. The CTD and mRNA Export. While the connection
between mRNA processing and the CTD has been
established, recent studies have begun to investigate
CTD involvement with the last step in mRNA production:
formation of an export competent messenger ribonucleo-
protein particle (mRNP). While this area of research has yet
to mature, it is known that mRNAs are exported through a
Ran-GTP-independent pathway that involves a speciﬁc set
of conserved export receptor and adaptor proteins. There
appears to be one universal receptor for mRNA export,
Mex67/Mtr2 in yeast and TAP/p15 in mammals, which
interacts with the mature mRNP and the nuclear pore
complex (NPC) to facilitate export. The export receptor
functions in conjunction with the export adaptor proteins,
which cotranscriptionally associate with the nascent mRNA.
There are two main mRNA export adaptor proteins,
Yra1/ALY in the transcription and mRNA export (TREX)
complex and Sac3 in the TREX-2 complex. While export
mediated by TREX-2 and Sac3 has been shown to be coupled
to chromatin modiﬁcation through Sus1, a common factor
in both TREX-2 and the Spt-Ada-Gcn5 acetyltransferase
(SAGA) complex (reviewed in [159, 160]), we will focus on
the novel connection between mRNA export by Yra1 and the
CTD.
TREX was the ﬁrst characterized transcription export
complex and consists of the THO complex of elongation and
hyperrecombination-related factors, including Hpr1, Tho2,
Thp1, and Mft1; the export adaptor protein Yra1/ALY; the
RNA helicase Sub2/UAP56; a protein of unknown function,
Tex1 [161]. Yra1/ALY has been proposed to link aspects
of mRNA splicing and processing to mRNA export based
on its interactions with Sub2/UAP56 [162, 163] and Pcf11
[164] and the observation that ALY may be associated with
the exon junction complex in mammals [165–167]. The
Hpr1 subunit of THO has been hypothesized to play an
important role in Yra1 and Sub2 recruitment because Δhpr1
yeast displays a decrease in the levels of both Sub2 and Yra1
occupancy on certain genes [168]; however, as deletion of
HPR1 has been shown to aﬀect transcription elongation, this
decrease in Yra1 and Sub2 occupancy may be due to an
elongation defect rather than a direct eﬀect of Hpr1 on the
export proteins [169].
I nap r e v i o u ss t u d yf r o mo u rl a b ,ap r o t e o m i c ss c r e e ni n
yeast identiﬁed Yra1 as a putative phospho-CTD-associated
protein (PCAP) [170]. We have since characterized the
phospho-CTD- (PCTD-) binding activity of this export
adaptor and demonstrated (via ChIP) that partial deletion
of its phospho-CTD interaction domain (PCID) leads to a
near loss of Yra1 association with active genes (MacKellar
and Greenleaf, In press (J. Biol. Chem.)). We therefore think
that either Yra1 is responsible for recruiting the rest of TREX
to active genes via the CTD or Yra1 is recruited to active
genes independently of THO. Further chromatin immuno-
precipitation studies using additional Yra1 variants that do
not bind the CTD are needed to further clarify the role of
the CTD in Yra1 function and the dependence of the rest of
TREX on Yra1.
We also found that the PCID of Yra1 contains an RNA
recognition motif (RRM). While RRMs are known to be
versatile-binding domains that mediate both protein-nucleic
acid and protein-protein interactions (see [171, 172]a n d
references therein), until this year no protein had been
found to use an RRM for PCTD binding. However, a
recent study on spliceosomal factor U2AF65 indicated that
its noncanonical RRM (also called a U2A homology motif
(UHM)) might also mediate an interaction between the
splicing factor and the PCTD [148]. We propose that there
is a class of factors that use its RRM as a dual-purpose
domainﬁrstforassociatingwiththetranscriptionelongation
complex via PCTD binding and then for associating with
the nascent transcript through RNA binding. Structural
studies on Yra1 in complex with the PCTD are necessary
to examine the role and binding mode of the RRM in this
interaction.
Based on our discovery that the CTD is involved in
recruiting Yra1 to genes, we have revised the model of Yra1
cotranscriptional recruitmenttoinclude theCTD(Figure 2).
We propose that Yra1 (possibly in complex with THO and
Sub2)isrecruitedtoactivegenesduringelongationwhenthe
CTD is doubly phosphorylated on Ser2 and Ser5. Because
we do not yet know whether Yra1 can bind both the CTD
and TREX, it is modeled in both contexts. As the nascent
mRNA grows, Yra1 remains bound to the CTD, and this may
prevent Yra1 from blocking the activities of other mRNA
processing factors, averting premature export. At the 3  end
of the gene, Yra1 dissociates from the CTD, because either
the phosphorylation pattern changes to predominantly Ser2
phosphorylation (which Yra1 does not bind) or Yra1 binds
the nascent mRNA with higher aﬃnity. This model is still
largely speculative, and further experimentation is required
to test the hypotheses it represents.10 Genetics Research International
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Figure 2:CTD-mediatedrecruitmentofYra1.Yra1(possiblyincomplexwithTHOandSub2)doesnotbindtoSer5PcontainingCTDandis
not observed at high level at the 5  end of genes. Yra1 is recruited to active genes during elongation when the CTD is doubly phosphorylated
on Ser2 and Ser5. As it is not known whether Yra1 can bind both the CTD and TREX, it is modeled in both contexts. Yra1 remains
bound to the CTD until the nascent mRNA reaches a certain length or reaches the CTD-bound Yra1; this would avert premature export
attempts. At the 3  end of the gene, Yra1 dissociates from the CTD, either because the phosphorylation pattern changes to predominant Ser2
phosphorylation (in which Yra1 does not bind) or because Yra1 binds the nascent mRNA with higher aﬃnity.
5.7. The Next Frontier in CTD Research: DNA Damage and
Repair. Results connecting transcription/RNA processing
with recombination and DNA damage repair have been
obtained in bacteria, yeast, and mammals (reviewed in
[173]). For example, defects in mRNA splicing (by ASF/SF2
in mammals) and packaging (THO/TREX and TREX-2 in
yeast) have been linked to genomic instability and hyper-
recombination via R-loop formation [174–176]. A potential
involvementoftheCTDinrepair/recombinationissuggested
by the observations that mutations in the subunits of the
CTDK-I kinase render yeast sensitive to DNA-damaging
agents and that DNA damage leads to alterations in the
phosphorylation pattern of the CTD [177]. Moreover, recent
work hints that the CTD and its associated proteins play a
role in sensing DNA damage and promoting repair.
For example, Bennett and colleagues used the diploid
yeast deletion strain collection to identify a large number of
geneswhosehomozygousdeletionleadstoionizingradiation
(IR) sensitivity [178, 179]. We have found that a signiﬁcant
number of these genes encode phospho-CTD-associating
proteins (PCAPs), thus linking IR damage repair to the
phospho-CTD (Winsor et al., in prep). A diﬀerent kind of
damage repair, as signaled by mitotic recombination, also
appears PCTD linked since diploid yeast deleted for CTK1
(ctk1Δ/ctk1Δ strains) displays reduced rates of spontaneous
mitotic recombination at several loci (Winsor et al., in prep).
Thus, the PCTD appears to be involved in processes that
maintain genome stability.
In a related vein, it was shown recently that mammalian
RecQ5 protein, a putative “antirecombinase,” is associated
with RNAPII on active genes [180, 181]. In vitro experi-
ments showed that RecQ5 binds directly to the elongation-
associated phospho-CTD via a Set2 Rpb1-interaction (SRI)
domain; moreover, deletion of the SRI domain resulted in
loss of RecQ5 protein at multiple loci [182]. While the
functionofRecQ5inRNAPIIelongationcomplexesisnotyet
known, we favor a model in which it remains poised on the
PCTD, ready to act if the polymerase encounters a situation
thatmightinduceinappropriatetranscription-linkedrecom-
bination (e.g., [174–179]). It will be extremely informative
to analyze the involvement of transcribing RNAPII, and
proteins associated with its PCTD, in repair/recombination
events that contribute to genome stability.
6. Conclusions
After 25 years of research, much is still unknown about the
CTD of RNAPII and its role in coordinating a surprising
number of nuclear events with transcription. In addition
to transcript elongation (RNAPII movement along the
template), mRNA processing, and chromatin modiﬁcation,
the collection of CTD-interacting processes is now thought
to also include mRNA export and DNA repair; future
investigations into the links between these events and the
CTD should be remarkably informative. New information
on CTD phosphorylation patterns, which modulate its
interactionswithnuclearfactors,hasrecentlybeengenerated
through genome-wide ChIP experiments, and multiple new
insights into global CTD phosphorylation have emerged. On
the other hand, the complexity and nuance of the patterns
of post-translational modiﬁcations are such that the actual
distribution of phosphate groups along the CTD is not
known for even one transcription elongation complex. Thus,
while the inventory of CTD-modifying enzymes continues
to expand, it is clear that we have much to learn about
the ways in which they collaborate to produce modiﬁcation
patterns as found in vivo. Even so, the list of proteins
known to interact with a speciﬁcally modiﬁed form of the
CTD also continues to grow, expanding our knowledge of
the roles played by the CTD in coordinating transcription-
related processes. As our knowledge of CTD modiﬁcations
and interactions expands and becomes more reﬁned, our
understanding of the “phospho-CTD cycle” and the manner
in which the PCTD orchestrates the numerous events
connected to the process of DNA-dependent RNA synthesis
will continue to evolve.
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